219 related articles for article (PubMed ID: 28751743)
1. Anti-AMPA GluA3 antibodies in Frontotemporal dementia: a new molecular target.
Borroni B; Stanic J; Verpelli C; Mellone M; Bonomi E; Alberici A; Bernasconi P; Culotta L; Zianni E; Archetti S; Manes M; Gazzina S; Ghidoni R; Benussi L; Stuani C; Di Luca M; Sala C; Buratti E; Padovani A; Gardoni F
Sci Rep; 2017 Jul; 7(1):6723. PubMed ID: 28751743
[TBL] [Abstract][Full Text] [Related]
2. Anti-GluA3 antibodies in frontotemporal dementia: effects on glutamatergic neurotransmission and synaptic failure.
Palese F; Bonomi E; Nuzzo T; Benussi A; Mellone M; Zianni E; Cisani F; Casamassa A; Alberici A; Scheggia D; Padovani A; Marcello E; Di Luca M; Pittaluga A; Usiello A; Borroni B; Gardoni F
Neurobiol Aging; 2020 Feb; 86():143-155. PubMed ID: 31784278
[TBL] [Abstract][Full Text] [Related]
3. GluA3 autoantibodies induce alterations in dendritic spine and behavior in mice.
Scheggia D; Stanic J; Italia M; La Greca F; Zianni E; Benussi A; Borroni B; Di Luca M; Gardoni F
Brain Behav Immun; 2021 Oct; 97():89-101. PubMed ID: 34246733
[TBL] [Abstract][Full Text] [Related]
4. Anti-GluA3 autoantibodies define a new sub-population of frontotemporal lobar degeneration patients with distinct neuropathological features.
Italia M; Salvadè M; La Greca F; Zianni E; Pelucchi S; Spinola A; Ferrari E; Archetti S; Alberici A; Benussi A; Solje E; Haapasalo A; Hoffmann D; Katisko K; Krüger J; Facchinetti R; Scuderi C; Padovani A; DiLuca M; Scheggia D; Borroni B; Gardoni F
Brain Behav Immun; 2024 May; 118():380-397. PubMed ID: 38485064
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup.
Woollacott IOC; Nicholas JM; Heslegrave A; Heller C; Foiani MS; Dick KM; Russell LL; Paterson RW; Keshavan A; Fox NC; Warren JD; Schott JM; Zetterberg H; Rohrer JD
Alzheimers Res Ther; 2018 Aug; 10(1):79. PubMed ID: 30111356
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype.
Woollacott IOC; Nicholas JM; Heller C; Foiani MS; Moore KM; Russell LL; Paterson RW; Keshavan A; Schott JM; Warren JD; Heslegrave A; Zetterberg H; Rohrer JD
Dement Geriatr Cogn Disord; 2020; 49(1):56-76. PubMed ID: 32344399
[TBL] [Abstract][Full Text] [Related]
7. Autoimmunity and Frontotemporal Dementia.
Alberici A; Cristillo V; Gazzina S; Benussi A; Padovani A; Borroni B
Curr Alzheimer Res; 2018; 15(7):602-609. PubMed ID: 29357796
[TBL] [Abstract][Full Text] [Related]
8. Toward a Glutamate Hypothesis of Frontotemporal Dementia.
Benussi A; Alberici A; Buratti E; Ghidoni R; Gardoni F; Di Luca M; Padovani A; Borroni B
Front Neurosci; 2019; 13():304. PubMed ID: 30983965
[TBL] [Abstract][Full Text] [Related]
9. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study.
Abu-Rumeileh S; Mometto N; Bartoletti-Stella A; Polischi B; Oppi F; Poda R; Stanzani-Maserati M; Cortelli P; Liguori R; Capellari S; Parchi P
J Alzheimers Dis; 2018; 66(2):551-563. PubMed ID: 30320576
[TBL] [Abstract][Full Text] [Related]
11. Modelling frontotemporal dementia using patient-derived induced pluripotent stem cells.
Lines G; Casey JM; Preza E; Wray S
Mol Cell Neurosci; 2020 Dec; 109():103553. PubMed ID: 32956830
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal Fluid Progranulin, but Not Serum Progranulin, Is Reduced in GRN-Negative Frontotemporal Dementia.
Wilke C; Gillardon F; Deuschle C; Hobert MA; Jansen IE; Metzger FG; Heutink P; Gasser T; Maetzler W; Blauwendraat C; Synofzik M
Neurodegener Dis; 2017; 17(2-3):83-88. PubMed ID: 27760429
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid from frontotemporal dementia patients is toxic to neurons.
Spalloni A; Caioli S; Bonomi E; Zona C; Buratti E; Alberici A; Borroni B; Longone P
Biochim Biophys Acta Mol Basis Dis; 2021 Jun; 1867(6):166122. PubMed ID: 33713790
[TBL] [Abstract][Full Text] [Related]
14. Pathophysiological aspects of frontotemporal dementia--emphasis on cytoskeleton proteins and autoimmunity.
Sjögren M; Wallin A
Mech Ageing Dev; 2001 Nov; 122(16):1923-35. PubMed ID: 11589911
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late-Onset Behavioral Variants of Frontotemporal Dementia.
Marelli C; Hourregue C; Gutierrez LA; Paquet C; Menjot de Champfleur N; De Verbizier D; Jacob M; Dubois J; Maleska AM; Hirtz C; Navucet S; Bennys K; Dumurgier J; Cognat E; Berr C; Magnin E; Lehmann S; Gabelle A
J Alzheimers Dis; 2020; 74(3):903-911. PubMed ID: 32083577
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal Fluid TAR DNA-Binding Protein 43 Combined with Tau Proteins as a Candidate Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Spectrum Disorders.
Bourbouli M; Rentzos M; Bougea A; Zouvelou V; Constantinides VC; Zaganas I; Evdokimidis I; Kapaki E; Paraskevas GP
Dement Geriatr Cogn Disord; 2017; 44(3-4):144-152. PubMed ID: 28848086
[TBL] [Abstract][Full Text] [Related]
17. Autoimmune epilepsy: some epilepsy patients harbor autoantibodies to glutamate receptors and dsDNA on both sides of the blood-brain barrier, which may kill neurons and decrease in brain fluids after hemispherotomy.
Ganor Y; Goldberg-Stern H; Amrom D; Lerman-Sagie T; Teichberg VI; Pelled D; Futerman AH; Zeev BB; Freilinger M; Verheulpen D; Van Bogaert P; Levite M
Clin Dev Immunol; 2004; 11(3-4):241-52. PubMed ID: 15559370
[TBL] [Abstract][Full Text] [Related]
18. Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest.
Foiani MS; Cicognola C; Ermann N; Woollacott IOC; Heller C; Heslegrave AJ; Keshavan A; Paterson RW; Ye K; Kornhuber J; Fox NC; Schott JM; Warren JD; Lewczuk P; Zetterberg H; Blennow K; Höglund K; Rohrer JD
J Neurol Neurosurg Psychiatry; 2019 Jul; 90(7):740-746. PubMed ID: 30981993
[TBL] [Abstract][Full Text] [Related]
19. Antinuclear antibodies in Frontotemporal Dementia: the tip's of autoimmunity iceberg?
Cavazzana I; Alberici A; Bonomi E; Ottaviani R; Kumar R; Archetti S; Manes M; Cosseddu M; Buratti E; Padovani A; Tincani A; Franceschini F; Borroni B
J Neuroimmunol; 2018 Dec; 325():61-63. PubMed ID: 30391902
[TBL] [Abstract][Full Text] [Related]
20. Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.
Levite M
J Neural Transm (Vienna); 2014 Aug; 121(8):1029-75. PubMed ID: 25081016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
